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Cytochrome c oxidaseMutations in human SCO2 gene, encoding the mitochondrial inner membrane Sco2 protein, have been found
to be responsible for fatal infantile cardioencephalomyopathy and cytochrome c oxidase (COX) deﬁciency.
One potentially fruitful therapeutic approach for this mitochondrial disorder should be considered the
production of human recombinant full length L-Sco2 protein and its deliberate transduction into the
mitochondria. Recombinant L-Sco2 protein, fused with TAT, a Protein Transduction Domain (PTD), was
produced in bacteria and puriﬁed from inclusion bodies (IBs). Following solubilisation with L-arginine, this
fusion L-Sco2 protein was transduced in cultured mammalian cells of different origin (U-87 MG, T24, K-562,
and patient's primary ﬁbroblasts) and assessed for stability, transduction into mitochondria, processing and
impact on recovery of COX activity. Our results indicate that: a) L-Arg solution was effective in solubilising
recombinant fusion L-Sco2 protein, derived from IBs; b) fusion L-Sco2 protein was delivered successfully via
a time- and concentration-dependent process into the mitochondria of human U-87 MG and T24 cells; c)
fusion L-Sco2 protein was also transduced in human K-562 cells, transiently depleted of SCO2 transcripts and
thus COX deﬁcient; transduction of this fusion protein led to partial recovery of COX activity in such cells; d)
[35S]Methionine-labelled fusion L-Sco2 protein, produced in a cell free transcription/translation system and
incubated with intact isolated mitochondria derived from K-562 cells, was efﬁciently processed to yield the
corresponding mature Sco2 protein, thus justifying the potential of the transduced fusion L-Sco2 protein to
successfully activate COX holoenzyme; and ﬁnally, e) recombinant fusion L-Sco2 protein was successfully
transduced into the mitochondria of primary ﬁbroblasts derived from SCO2/COX deﬁcient patient and
facilitated recovery of COX activity. These ﬁndings provide the rationale of delivering recombinant proteins
via PTD technology as a model for therapeutic approach of mitochondrial disorders.co2 protein, recombinant fusion
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Mutations in human SCO2 gene have been implicated in de-
generative diseases, like fatal infantile cardioencephalomyopathy and
cytochrome c oxidase (COX) deﬁciency [1,2]. The human inner
membrane mitochondrial mature Sco2 protein is a COX assembly
protein, relatively hydrophobic, involved in mitochondrial coppertransfer [3,4], mitochondrial redox signalling [5] and the p53
regulatory pathway in mitochondria [6,7]. Based on our previous
work [3], different pointmutations in SCO2 gene seem to exert distinct
alterations in the physical conformation state of the native mito-
chondrial mature Sco2 protein, thus promoting or disturbing the
copper binding capacity. Unfortunately, still there is no effective
therapy of such disorders [8]. However, based on the existing exper-
imental methodology using protein transduction technology of
efﬁciently delivering functional recombinant proteins within the
cells [9,10], we reasonably considered this approach as a potential
therapeutic strategy to treat SCO2-related COX deﬁcient disorders.
Protein transduction technology, based on the ability of short
amino acid sequences [termed Protein Transduction Domains (PTDs)
or Cell Penetrating Peptides (CPPs)] to facilitate transduction of
exogenously produced recombinant proteins into mammalian cells
[9–14], could be considered as an alternative approach for the treat-
ment of metabolic/genetic disorders [15,16]. TAT is an 11aa sequence
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ciency Virus-1 (HIV-1) and has been one of themost widely used PTDs
[9,14,17].
Protein transduction technology could allow intracellular deliv-
ery of recombinant human L-Sco2 protein. Since human full length L-
Sco2 protein consists of 266aa, including the ﬁrst 41aa that
correspond to the N-terminal leader peptide (L), it was critical to
clone, express and produce the recombinant L-Sco2 protein in fusion
with the TAT as PTD. The produced fusion L-Sco2 protein could be
delivered intracellularly into mammalian cells and, in particular,
within their mitochondria. Here, we provide evidence that human
recombinant full length L-Sco2 protein, produced in bacteria and
solubilised in 1 M L-Arg, can be intracellularly delivered into the
mitochondria of different types of mammalian cells (U-87 MG, T24,
and K-562). In addition, [35S]Methionine-labelled fusion L-Sco2
protein was produced in a cell free transcription/translation system
and incubated with isolated intact mitochondria. The latter study
aimed to demonstrate whether recombinant fusion L-Sco2 protein is
processed appropriately by the MPP, the matrix-located mitochon-
drial processing peptidase [18–22], to yield mature protein inside
the mitochondria of mammalian cultured cells. This step is
considered critical for this protein to exert its function and restore
COX activity in cells deﬁcient of endogenous SCO2 transcripts.
Additionally, fusion L-Sco2 protein was transduced in primary
ﬁbroblasts derived from SCO2/COX deﬁcient patient M.C., to
demonstrate recovery of suppressed COX activity. These cells are
compound heterozygous (Q53X and E140K) concerning SCO2
mutations [1], with 30% residual COX activity in ﬁbroblasts
compared to controls. E140K is a missense mutation nearby the
copper binding motif (CXXXC) of Sco2 protein, harboured by almost
all patients carrying mutations in SCO2 gene [1], converting Glu-140
to Lys on the one allele, while Q53X is a nonsense mutation on the
other allele, leading to an endogenous mature protein of only 12aa
compared to 225aa of native mature Sco2 protein. It is interesting to
say that patients homozygous for E140K had a milder phenotype
compared with patients compound heterozygous with a null allele,
like the Q53X nonsense mutation.
2. Materials and methods
2.1. Cloning and expression vectors
pTAT/TAT-HA is a bacterial expression vector containing an N-
terminal His6 peptide followed by the 11aa TAT Protein Transduction
Domain (YGRKKRRQRRR), a hemagglutinin (HA) tag and a multiple
cloning site (MCS) [23,24]. The TA Cloning® Kit with pCR®2.1 vector
provides a quick, one step cloning strategy for the direct insertion of
a PCR product into a plasmid vector (Invitrogen Life Technology Inc.,
U.S.A.). The fusion expression pET-16b vector (Novagen, Germany)
used throughout this study, contains an IPTG-inducible T7 promoter
and an N-terminal His10 peptide followed by a XaSITE, adjacent to the
MCS. The XaSITE is the cleavage site for Factor Xa protease (QIAGEN
GmbH, Germany).
2.2. Construction of the recombinant bacterial expression
pET-16b-TAT-L-SCO2-HA vector: cloning strategy
A clone of full lengthwild-typeDNAof human SCO2 gene (GenBank
accession no: AF177385)was derived from a healthy individual [1] via
PCR ampliﬁcation, using the 5′-AGGGAGCTGGAGGTCGGCGCTTC-3′
(23mer) as forward primer and the 5′-CAGCCCGTTTAATGATGGGGC-
3′ (21mer) as reverse primer. The PCR product (1960 bp) obtained
was then subcloned inpGEM®–T vector (Promega Ltd., UK). Using total
RNA from the healthy individual as template and the same primers
the corresponding cDNA (913 bp) was ampliﬁed via RT-PCR. This
was further subcloned in pGEM®–T vector as well as in pcDNA3mammalian expression vector (Invitrogen Life Technologies Inc.,
U.S.A.), containing an IPTG-inducible T7 promoter. This cDNA served
also for ampliﬁcation, using the 5′-ATGCTGCTGCTGACTCGGAGCCCCA-
CAGCTTGG-3′ (33mer) as forward primer and the 5′-TCAAGACAGGA-
CACTGCGGAAAGCCG-3′ (26mer) as reverse primer, of the coding
sequence (CDS) of 801 bp (L-SCO2), encoding the human full length L-
Sco2 protein. L-Sco2 protein consists of 266aa, including the ﬁrst 41aa,
predicted to correspond to the N-terminal leader peptide (L) or
Mitochondrial Targeting Signal peptide (MTS) (http://ihg2.helm-
holtz-muenchen.de/ihg/mitoprot.html) (Fig. 1A). Three recombinant
plasmid vectors, according to the strategic plan shown in Fig. 1, were
constructed as follows:
Step 1: pCR®2.1-TAT-HA construct. By using the 5′-CGAGGTACCAAC-
TACGGCCGCAAGAAACGC-3′ (30mer, containing a Kpn I site) as
forward primer and the 5′-CCGAATTCTCAAGCATAGTCTGGGACGTC-
3′ (29mer, containinganEcoR I site) as reverseprimer, a Kpn I/EcoR I
fragment of TAT-HA (∼100 bp) (Fig. 1B) from pTAT/pTAT-HA vector
(annealing temperature at 58 °C) was PCR regenerated and then
ligated into the pCR®2.1 vector (Fig. 1C).
Step 2: pCR®2.1-TAT-L-SCO2-HA construct. By using the 5′-
CGGGATCCCTGCTGCTGACTCGGAGC-3′ (26mer, containing a BamH
I site) as forward primer and the 5′-GGGGATCCAGACAGGA-
CACTGCGG-3′ (24mer, containing a BamH I site) as reverse primer,
BamH I/BamH I fragment, corresponding to L-SCO2 CDS, was PCR
ampliﬁed (annealing temperature at 55 °C, in the presence of 10% v/
v DMSO) from the original clone (pGEM®-T vector) and then ligated
into BamH I site of the pCR®2.1-TAT-HA vector to give birth to
pCR®2.1-TAT-L-SCO2-HA recombinant construct (Fig. 1C).
Step 3: pET-16b-TAT-L-SCO2-HA construct. By using the 5′-
CGAATTCCATATGTACGGCCGCAAGAAACGC-3′ (31mer, containing
a Nde I site) as forward primer and the 5′-CAACTCGAGTCAAGCA-
TAGTCTGGGAC-3′ (27mer, containing a Xho I site) as reverse
primer, a PCR ampliﬁed Nde I/Xho I fragment of TAT-L-SCO2-HA
from pCR®2.1-TAT-L-SCO2-HA (annealing temperature at 58 °C, in
the presence of 10% v/v DMSO) was regenerated and then ligated
into the pET-16b vector (Fig. 1C). Recombinant constructs bearing
the correct insert in the right orientation were selected and
veriﬁed by automatic sequence analysis (Macrogen Inc., South
Korea; Lark Technologies, Inc., UK).
2.3. Plasmid DNA isolation and analysis of recombinant protein
Preparation of DNA fragments, ligation and transformation of
E. coli [INVaF, TOP10F and BL21 (DE3)] competent cells, plasmid DNA
isolation (Invitrogen Life Technologies Inc., U.S.A.) as well as SDS-
PAGE (10–12% w/v) and western blot immunostaining analysis were
carried out as previously described [3,25].
2.4. Transformation of bacterial competent cells—inducible expression,
production and solubilisation of recombinant His10-XaSITE-TAT-L-Sco2-HA
(fusion L-Sco2) protein
Recombinant pCR®2.1-TAT-HA and pCR®2.1-TAT-L-SCO2-HA
clones were selected to transform E. coli INVaF, while pET-16b-TAT-
L-SCO2-HA clones were selected to transform E. coli Τop10F and BL21
(DE3) competent cells. A selected colony of transformed by pET-16b-
TAT-L-SCO2-HA bacterial BL21 (DE3) cells was cultured in L.B.
medium, containing ampicillin (50 g/ml). Induction was performed
with 0.5 mM IPTG at 37 °C for 4 h. Bacterial pellet was harvested in
order to produce inclusion bodies (IBs), which were further puriﬁed
[3,25].
Puriﬁed IBs were isolated and dissolved in 1 M L-Arg (Sigma-Aldrich,
St. Louis, U.S.A.) solution (20 mM Tris–HCl pH 7.5). Solubilised IBs were
then centrifuged at 2500×g and the supernatant, containing the
recombinant His10-XaSITE-TAT-L-Sco2-HA (fusion L-Sco2) protein, was
Fig. 1. Structural domains of the full length L-Sco2 protein, cloning strategy and characteristic tags of the recombinant His10-XaSITE-TAT-L-Sco2-HA (fusion L-Sco2) protein, intended
for intracellular delivery. (A) Domains of full length human mitochondrial L-Sco2 protein [5]: L: leader peptide, corresponding to MTS; TM: transmembrane; IMS: intramembrane
space, containing the core region of the L-Sco2 protein including the conserved copper binding motif (C133XXXC137) plus the conserved His (H224). The potential site of MPP action is
also shown with an arrow. (B) TAT-HA sequence from pTAT/pTAT-HA vector, including the unique BamH I recognition site used for the insertion of L-SCO2 CDS. (C) Cloning strategy
for the construction of pET-16b-TAT-L-SCO2-HA vector. (D) Domains of the recombinant His10-XaSITE-TAT-L-Sco2-HA fusion protein. Horizontal arrow indicates the N-terminal
protein region, predicted by Mitoprot web tool, to be recognised as MTS. The potential site of MPP action is also shown with a vertical arrow.
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dissolved in 1 M L-Arg solution was found to be stable for at least
2 months.
2.5. Analysis of recombinant protein
Puriﬁed IBs, containing the fusion L-Sco2 protein were resolved
by 12% w/v SDS-PAGE analysis, transferred on nitrocellulose
membrane (Schleicher & Schuell, Dassel, Germany) and immunos-
tained with either puriﬁed polyclonal antiserum raised against
rhSco2w/t protein (anti-Sco2.IgG) [3] (1:700) or mouse monoclonal
anti-HA.IgG 16B12 antibody (1:4000) (Alexa Fluor conjugate,
Molecular Probes-Invitrogen Life Technologies Inc., U.S.A.). Goat
anti-rabbit IgG-AP (Sigma-Aldrich, St. Louis, U.S.A.) (1:2500) or goat
anti-mouse IgG-AP (Santa Cruz Biotechnology, CA, U.S.A.) (1:1000)
were used as secondary antibodies and the signal was detected with
the BCIP/NBT colour development assay. Alpha-tubulin mouse
monoclonal antibody (clone TU-16) (BioVentor Laboratory Medi-
cine, Inc., CTParkModrice, Czech Republic) was used (1:500) in order
to quantitate the cytosolic fraction of cells.
2.6. Cell cultures
Adherent human U-87 MG glioblastoma cells [26], human T24
urinary bladder carcinoma cells [27], human Hep G2 hepatoma-derived cells [28] and human embryonic 293T kidney cells [29] were
cultured in Dulbecco's Modiﬁed Eagle's Medium (DMEM) supple-
mented with 10% v/v FBS, streptomycin (1 µg/ml) and penicillin
(1 U/ml) (Gibco-Invitrogen, Life Technologies Inc., U.S.A.). The cells
were maintained in exponential growth at 37 °C, in 5% CO2
humidiﬁed atmosphere, by passing via trypsinization. Human K-
562 erythroleukemia cells [30] were seeded in suspension culture at
a concentration of 2–3×105 cells/ml in RPMI-1640 (Gibco-Invitro-
gen, Life Technologies, Inc., U.S.A.) supplemented with 10% v/v FBS,
streptomycin (1 µg/ml) and penicillin (1 U/ml) and maintained in
exponential growth at 37 °C, in 5% CO2 humidiﬁed atmosphere. Cell
number was determined at indicated time points by using a
Neubauer hematocytometer under a light microscope, while cell
viability was assessed by using the trypan-blue (Sigma-Aldrich, St.
Louis, U.S.A.) exclusion assay [31]. Primary ﬁbroblasts, derived from
SCO2 deﬁcient patient M.C. with compound heterozygous (Q53X and
E140K) mutations [1], were grown as monolayer culture in DMEM,
supplemented with 15% v/v FBS, streptomycin (1 µg/ml) and
penicillin (1 U/ml).
2.7. Total cytoplasmic protein isolation
Human cultured cells (K-562, U-87 MG, T24, Hep G2 and 293T)
were harvested, washed twicewith PBS (1×) and lysedwith RIPA lysis
buffer (150 mM NaCl, 0.1% w/v SDS, 1% v/v NP-40, 1% w/v sodium
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supplemented with protease inhibitors cocktail (Sigma-Aldrich, St.
Louis, U.S.A.). Sampleswere disrupted by repeatedly passages through
a 3 gauge (insulin) needle and centrifuged at 10 000×g for 15 min at
4 °C to collect supernatant, corresponding to the total cytoplasmic
proteins.
2.8. RNA isolation and northern blot hybridization analysis
Total RNA (from human K-562, U-87 MG, T24 and 293T cell lines)
was extracted according to acid quanidium thiocyanate–phenol–
chloroform extraction method [32]. Formaldehyde-denatured RNA
samples (∼12 µg) were electrophoretically separated on 1.2% w/v
agarose–2.2 M formaldehyde gel, transferred onto a nylon membrane
in 20× SSC, immobilized by UV light for 5 min and hybridized at 65 °C
[33]. A radiolabelled probe was made using the multiprime DNA
labelling system kit (Invitrogen, Life Technologies Inc., U.S.A.) with
[a-32P]dCTP. A probewas used a PCR fragment (836 bp) being ampliﬁed
by 5′-ATGCTGCTGCTGACTCGGAGCCCCACAGCTTGG-3′ (33mer) as for-
ward primer and the 5′-CAGCCCGTTTAATGATGGGGC-3′ (21mer) as
reverse primer. The ﬁlters were washed and autoradiographed using
KodakXAR-5ﬁlm. Theﬁlmswere exposed at low temperature (−70 °C)
and autoradiographs were developed.
2.9. RT-PCR analysis
Total RNA isolated from human K-562 cells was used for RT-PCR
experiments (1 µg/reaction) in order to determine endogenous
levels of SCO2 mRNA transcripts. Total RNA from these samples
was also used (1 µg/reaction) for the detection of steady state
mRNA levels of other structural or COX assembly genes. One step
RT-PCR was performed with the RobusT-I RT-PCR kit (FINNZYMES).
The RT-PCR running conditions were the following: 50 °C for
30 min, 94 °C for 2 min, [94 °C for 30 s, × °C for 1 min, 72 °C for
1 min] for 30 cycles and 72 °C for 10 min. GAPDH was used as
internal control.
The used primer sequence pairs, the annealing temperatures (×°C)
and the predicted size for PCR products expected for each particular
gene tested are as follows:SCO2, 5′-AGGGAGCTGGAGGTCGGCGCTTC-3′ (sense) and
5′-CAGCCCGTTTAATGATGGGGC-3′ (anti-sense), 58 °C, 912 bp;
SCO1, 5′-AGTACCCGGACGAGTTATGC-3′ (sense) and
5′-TGCGAGACAGTTTCCTTCCT-3′ (anti-sense), 44 °C, 947 bp;
COX10, 5′-TTTTGAGGTGCCATTTGACTC-3′ (sense) and
5′-AACCCAGCAATTTCTCTTCTTG-3′ (anti-sense), 48 °C, 796 bp;
COX17, 5′-GGAAGTGACTGCAGACGAATCGG-3′ (sense) and
5′-AGTTCGTCAAAGAACTCCCA-3′ (anti-sense), 60 °C, 350 bp;
MTCOXI, 5′-AGGGGCCATCAATTTCATCACAAC-3′ (sense) and
5′-CACACGATAAACCCTAGGAAGCC-3′ (anti-sense) 51 °C, 386 bp;
MTCOXII, 5′-GCGACCTGCGACTCCTTGAC-3′ (sense) and
5′-GTGTAGCGGTGAAAGTGGTTTGG-3′ (anti-sense), 50 °C, 149 bp;
MTCOXIII, 5′-GATTTCACTTCCACTCCATAACGCTCC-3′ (sense) and
5′-AATGGTGAAGGGAGACTCGAAGTACTC-3′ (anti-sense), 51 °C,
436 bp;
COXIV-1, 5′-ATGTTGGCTACCAGGGTATTTA-3′ (sense) and
5′-CCACTCGTTCTTTTCGTAGTC-3′ (anti-sense), 44 °C, 501 bp;
COXVa, 5′-TCACAGGAGACAGATGAGGA-3′ (sense) and
5′-GTTCCTCCGGAGTGGAGATTC-3′ (anti-sense), 44 °C, 300 bp;
COXVIa-1, 5′-GAAGAGGGCTCAGCTCGCATG-3′ (sense) and
5′-TTCATCTTCGTAGCCAGTTGGA-3′ (anti-sense), 49 °C, 236 bp;
COXVIc, 5′-ATGGCTCCCGAAGTTTTGCC-3′ (sense) and
5′-CACTCTGAAAGATACCAGCC-3′ (anti-sense), 44 °C, 219 bp;
GAPDH, 5′-GAAGGTGAAGGTCGGAGT-3′ (sense) and
5′-GAAGATGGTGATGGGATTTC-3′ (anti-sense), 57 °C, 255 bp.2.10. Transduction of recombinant fusion L-Sco2 protein into human
cultured cells
U-87MG and T24 cells (60–80% at conﬂuency) aswell as K-562 cells
(6–8×105 cells/ml) were ﬁrst washed and then were incubated in
OptiMEM®I medium (Gibco-Invitrogen, Life Technologies Inc., U.S.A.),
either with 10–50 mM L-Arg or with IBs, enriched in fusion L-Sco2
protein and solubilised in 1 M L-Arg. For incubation times longer than
2 h, 1× volume of DMEM or RPMI-1640 medium (supplemented with
10% v/v FBS) was added. Prior to transduction experiments in K-562
cells, the recombinant fusion L-Sco2 protein (His10-XaSITE-TAT-L-Sco2-
HA) was further processed by incubation with Factor Xa protease
(1 U/50 µg of fusion protein) for 4 days at RT in order to remove the
His10 tag. Factor Xa protease was then removed via Xa Removal Resin
(QIAGENGmbH,Germany) (12.5 µl of the settled resin per unit of Factor
Xa protease) added for 2 extra days at RT. Resin beadswere removed by
low spin centrifugation. Primaryﬁbroblasts derived from SCO2 deﬁcient
patient (M.C.) [1] growing in culture were incubated with 10 µg/ml
(processed with Factor Xa protease) of fusion L-Sco2 protein, as earlier
described for K-562 cells.
2.11. Transient suppression of cytochrome c oxidase (COX) activity in
K-562 cells
It was reasonable for the needs of the experiment to ﬁrst suppress
the SCO2 gene expression and thus COX activity in cultured cells and
then transduce the fusion L-Sco2 protein in these cells to demonstrate
whether the transduced recombinant protein is able to restore COX
activity. For this reason, we exploited the unique ability of anti-
leukemic agent Imatinib (IM) to suppress selectively SCO2 gene
expression in K-562 cells. Thus, by treating K-562 cells with IM (1 µM)
for 48 and 72 h and assessing these cells by RT-PCR for SCO2 as well as
other mRNA transcripts encoded by genes playing critical role in the
function of COX holoenzyme, we developed the appropriate condi-
tions of transiently SCO2 suppressed K-562 cells.
2.12. Subcellular fractionation and mitochondria isolation
U-87MG and T24 (60–80% at conﬂuency) as well as Κ-562 cultured
cells, incubated with or without the fusion L-Sco2 protein, were
harvested, washed twice with PBS (1×) and processed for subcellular
fractionation. Cytosol andmitochondriawere prepared by applying two
methods, A and B. Method A was used only in the preliminary
experiments with U-87 MG cells (Fig. 4), just qualitatively, to
demonstrate whether the fusion L-Sco2 protein is transduced into
mitochondria of cultured cells in a concentration-dependent fashion,
before proceeding to more detailed study of intracellular protein
delivery. Brieﬂy, U-87 MG cells were resuspended in 1.4 ml ice-cold
Mito-buffer solution (0.2 mMEDTA, 0.25 mMsucrose, and 10 mMTris–
HCl pH 8.0), supplemented with protease inhibitors cocktail and deep-
freezed for 0.5 h at −70 °C. Defrosted samples were disrupted by
repeatedly passages through a 21 gauge needle and centrifuged at
1000 ×g for 10 min at 4 °C to pellet nuclei and cellular debris. Post
nuclear supernatant obtained was then centrifuged at 10 000 ×g for
15 min at 4 °C to collect intact mitochondria, which were resuspended
inMito-buffer solution, supplementedwith protease inhibitors cocktail,
and stored at −70 °C. Method B: highly puriﬁed mitochondria were
prepared by using the Qproteome Mitochondria Isolation kit (QIAGEN
GmbH, Germany), according to the instructions of the manufacturer,
including an additional density gradient puriﬁcation step [34]. Brieﬂy,
cultured cells, after being harvested, were resuspended in ice-cold lysis
buffer. Since this buffer disrupts the plasma membrane without
solubilising the cells, cytosolic protein extracts were obtained. Pellet,
containing plasmamembranes and compartmentalized organelles, was
resuspended in the disruption buffer. After cell disruption, the
supernatant (containing mitochondrial and microsomal fraction) was
Fig. 2. SDS-PAGE analysis of puriﬁed inclusion bodies (IBs) containing the fusion L-Sco2
protein. Lane 1: Molecular Protein Weight Markers; lane 2: IBs derived from bacterial
mock cells and solubilised in 8 M urea; lanes 3, 4: IBs derived from induced bacterial
cells transformed with recombinant plasmid pET-16b-TAT-L-SCO2-HA (clones 1 and 2,
respectively) and solubilised in 8 M urea. Arrow indicates the position of fusion L-Sco2
protein.
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Following an additional density gradient puriﬁcation step, highly
puriﬁed mitochondria were obtained, resuspended in Mitochondria
Storage Buffer and stored at −70 °C. Protein content was measured
according to Bradford method [35].
2.13. In vitro production of fusion L-Sco2 protein in a cell free
transcription/translation system
[35S]Methionine-labelled fusion L-Sco2 protein was produced via in
vitro transcription/translation of TAT-L-SCO2-HA sequence in pET16b
expression vector by using the TNT®T7 Quick Coupled Transcription/
Translation System (Promega Ltd., UK) in the presence of [35S]
Methionine [N1000 Ci/mmol, 500 mCi/50 µl (IZOTOP; Institute of Iso-
topes Co., Ltd.)] for 90 min at 30 °C. The sameprocedurewas used for the
in vitro translation of SCO2 cDNA (913 bp, L-SCO2 sequence) in pcDNA3
in order to serve as a positive control. Isolated intact mitochondria,
derived from cultured Κ-562 cells, were resuspended (∼10 µg/µl) in
Mitochondrial Import Buffer (220 mM mannitol, 70 mM sucrose, and
5 mM Tris–HCl pH 7.5) and incubated with translation products (1:1
volume) for 2 h at 30 °C. By the end of this time, mitochondria were
collected,washed and treatedwith 5 µg/ml Proteinase K (PK) for 15 min
on ice, in order to digest and remove proteins not imported inside
mitochondria. By the end of this period, PK reactionwas terminatedwith
protease inhibitors cocktail for 10 min on ice, mitochondria were
harvested by centrifugation at 10 000 ×g for 10 min at 4 °C and analysed
with SDS-PAGE analysis. Fixed and dried gel was autoradiographedwith
an intensifying ﬁlm on Kodak XAR-5 ﬁlm at−70 °C for 10 days.
2.14. Enzymatic assessment of cytochrome c oxidase activity
The ability of cytochrome c oxidase (COX) to oxidize its natural
substrate cytochrome c (COX enzymatic activity) was evaluated
spectrophotometrically (UV–Vis, Hitachi U-2000; Japan) in isolated
mitochondria, according to the method described by Kirby et al. [36].
COX enzymatic activity was normalized against citrate synthase (CS)
activity, measured in the same samples (COX/CS).
2.15. Histochemical staining for COX activity
Primary ﬁbroblasts derived from SCO2/COX deﬁcient patient and
grown on glass coverslips in 24-well plates (Corning, U.S.A.), exposed
to none or incubated for 18 h either with ∼30 mML-Arg or with IBs,
enriched in fusion L-Sco2 protein and solubilised in 1 M L-Arg, were
washed with PBS (1×) and air-dried for 45 min at RT. Then, the cells,
attached on the glass coverslips, pre-incubated with 1 mM CoCl2 and
50 µl of DMSO in 50 mM Tris–HCl pH 7.6, containing 10% w/v sucrose,
for 15 min at RT. After rinsing once with 0.1× PBS:10% w/v sucrose
(1:1), the cells were incubated for 3 h, at 37 °C in 5% CO2 humidiﬁed
atmosphere, with 300 µl of substrate solution (10 mg of cytochrome c,
10 mg of diaminobenzidine, 2 mg of catalase and 25 µl of DMSO in
10 ml of 0.1× PBS pH 7.6, containing 10% w/v sucrose). In the
following step, cells (attached on coverslips) were incubated for 5 min
in 0.1× PBS:10% w/v sucrose (1:1), for another 5 min in PBS (1×) and
for 5 min in dH2O. After air-drying, the coverslips were mounted in
Entellan (containing xylene) (Merck, Germany), examined under an
inverted microscope (NIKON ECLIPSE TS100) and photos were taken
using a NIKON COOLPIX P5100 camera.
3. Results
3.1. PCR cloning
It was crucial from the beginning of this work to design and
produce full length humanmitochondrial L-Sco2 protein in bacteria as
a fusion recombinant protein with TAT domain as PTD (Fig. 1).According to our cloning strategy shown in Fig. 1C, the recombi-
nant bacterial expression vector pET-16b-TAT-L-SCO2-HA was con-
structed accordingly to produce the recombinant fusion His10-XaSITE-
TAT-L-Sco2-HA (fusion L-Sco2) protein, which could be delivered into
the cytosol and later on into mitochondria. The TAT sequence was
cloned just prior to the L-SCO2 CDS and the HA tag at the C-terminal
region, as illustrated in Fig. 1C. By employing the Mitoprot logismic
program (http://ihg2.helmholtz-muenchen.de/ihg/mitoprot.html),
the His10-XaSITE-TAT-L peptide of recombinant fusion L-Sco2 protein
was predicted as a MTS with a probability factor of 0.6107 (Fig. 1D).
Considering that cleavage of the His10-XaSITE-TAT-L-Sco2-HA protein
with Factor Xa protease to remove the His10 tag (prior to transduction
into cells) would yield fusion TAT-L-Sco2-HA protein, the TAT-L
peptide was predicted as MTS with a higher probability factor (0.91).
Upon successful transduction of fusion L-Sco2 protein inside
mitochondria, enzymatic cleavage by MPP should release mature
Sco2-HA protein (Fig. 1D), which is expected to be inserted into the
inner mitochondrial membrane and function properly.
3.2. Bacterial production of fusion L-Sco2 protein: puriﬁcation and
solubilisation of IBs
IPTG-induction of bacterial cells (being transformed with pET-
16b-TAT-L-SCO2-HA vector) led to the production of recombinant
fusion L-Sco2 protein ofMw ∼36 kDa. SDS-PAGE analysis, followed by
western blot immunostaining analysis with mouse monoclonal anti-
HA.IgG, conﬁrmed that themajority of produced fusion L-Sco2 protein
accumulated in the bacterial pellet (data not shown). Bacterial IBs,
puriﬁed, solubilised and analysed by SDS-PAGE, were found to be
enriched in recombinant fusion L-Sco2 protein (Fig. 2, lanes 3, 4).
Notably, no fusion protein was detected in IBs derived from mock
bacterial cells transformed with pET-16b vector and induced by IPTG
(Fig. 2, lane 2). Despite the observed high tendency of fusion L-Sco2
protein to aggregate, puriﬁed IBs (enriched in fusion L-Sco2 protein)
were well dissolved in 1 M L-Arg solution and the ﬁnal concentration
of the fusion protein was adjusted at 0.5–1.0 µg/µl. Western blot
immunostaining analysis (Fig. 4, lane 1) conﬁrmed the presence of a
relatively stable recombinant fusion L-Sco2 protein in 1 M L-Arg
solution for at least 2 months at RT.
3.3. Targeted intracellular delivery of fusion L-Sco2 protein into the
mitochondria of cultured mammalian cells
Three sets of experimentswere performed in order to demonstrate
the transduction of fusion L-Sco2 protein into cultured mammalian
Fig. 4. Western blot immunostaining detection of fusion L-Sco2 protein in the
mitochondria derived from U-87 MG cells, using the polyclonal anti-Sco2.IgG. Cultured
U-87 MG cells were incubated with 2.5, 5 or 10 µg/ml of solubilised fusion L-Sco2
protein for 1.5, 2.5 and 18 h. By the end of the incubation period, mitochondria were
isolated and fusion L-Sco2 protein was detected by western blot immunostaining
analysis. (A) Lane 1: 1 µg of IBs, enriched in recombinant L-Sco2 fusion protein and
solubilised in 1 M L-Arg; lane 2: Molecular Protein Weight Markers (M) lanes 3, 4, 5:
mitochondrial proteins (∼10 µg) of U-87 MG cells, following incubation for 2.5 h either
with 50 mM of 1 M L-Arg or 5 µg and 25 µg of solubilised fusion L-Sco2 protein per ml
culture, respectively. (B) Lane 1: 1 µg of IBs, enriched in recombinant L-Sco2 fusion
protein and solubilised in 1 M L-Arg; lane 2: Molecular Protein Weight Markers (M)
lanes 3, 4, 5: mitochondrial proteins (∼18 µg) of U-87MG cells, following incubation for
1.5 h either with 20 mM of 1 M L-Arg or 2.5 µg and 10 µg of fusion L-Sco2 protein per ml
culture, respectively; lanes 6, 7, 8: mitochondrial proteins (∼18 µg) of U-87 MG cells,
following incubation for 18 h either with 20 mM of 1 M L-Arg or 2.5 µg and 10 µg of
solubilised L-Sco2 fusion protein per ml culture, respectively.
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protein transduction experiments; b) time- and concentration-
dependent preliminary transduction studies with U-87 MG cells;
and c) kinetic analysis of the intracellular delivery of fusion L-Sco2
protein in both U-87 MG and T24 cell lines.
In particular: a) the selection of U-87MG and T24 adherent human
cell lines was based on their ability to produce SCO2mRNA transcript
(Fig. 3A) and accumulate the endogenous mature Sco2 protein of Mw
∼25 kDa in detectable levels, according to northern blot hybridization
andwestern blot immunostaining analysis data (Fig. 3C), as well as on
their relationship with tissues being primarily affected in SCO2
patients. U-87 MG and T24 adherent cells were selected as potential
acceptor human cell lines to demonstrate whether intracellular
transduction of recombinant fusion L-Sco2 protein is possible and
may be cell type speciﬁc. K-562 cells were also selected as a non-
adherent human cell line for transduction experiments; b) time-and
concentration-dependent protein transduction experiments were
carried out with U-87 MG cells to optimize the amount of fusion L-
Sco2 protein required for transduction experiments. U-87 MG cell
cultures were incubated for 1.5, 2.5 and 18 h with varying concentra-
tions (2.5, 5, 10 and 25 µg/ml of culture) of fusion L-Sco2 protein
under serum-free conditions (OptiMEM®I medium) for the ﬁrst 2 h,
favouring protein transduction. Assessment of cell viability, by the
trypan-blue exclusion assay, showed no substantial difference
between cells treated with 10–50 mM L-Arg or with the varying
concentrations of fusion L-Sco2 protein (data not shown). This ﬁnding
conﬁrmed that the fusion L-Sco2 protein added exogenously caused
no harm to the cells. SDS-PAGE analysis of the mitochondrial protein
fraction has shown that the recombinant fusion L-Sco2 protein was
detected in the mitochondrial fraction in the expected size of Mw
∼36 kDa (Fig. 4A, B), as indicated by western blot immunostaining
analysis using polyclonal anti-Sco2.IgG. Immunostaining detection
also conﬁrmed the presence of native endogenous mature Sco2
protein of Mw ∼25 kDa. Endogenous mature Sco2 protein was
identiﬁed in all mitochondrial samples prepared from either cells
treatedwith 1 M L-Arg solution only or incubated with IBs, enriched in
the recombinant fusion L-Sco2 protein and solubilised in 1 M L-Arg.
Mitochondria derived from U-87 MG cells and incubated with the
relatively higher concentrations of the fusion L-Sco2 protein (10 and
25 µg/ml culture) contained the exogenously added fusion L-Sco2
protein at a level comparable to that of endogenous Sco2 protein.
ImageJ web tool (http://rsb.info.nih.gov/ij/) was used for quantita-
tion (Fig. 4); c) Additional kinetic analysis, performed with 10 µg/ml
of fusion L-Sco2 protein, clearly showed that the delivery of fusion L-
Sco2 protein into mitochondria of U-87 MG cells was time-dependent
(Fig. 5). Parallel transduction experiments with T24 cells indicatedFig. 3.Northern blot hybridization analysis of humanmRNAs and western blot immunostain
from different human cell lines. (A) Total RNA samples (∼12 µg) isolated from human K-5
agarose–2.2 M formaldehyde gel, transferred onto a nylon membrane and hybridized at 65 °
washed at 65 °C and autoradiographed. (B) Agarose gel shows the corresponding ethidium b
rRNAs are indicated). (C) Total cytoplasmic protein extract (∼250 µg) isolated from K-562, U
SDS-PAGE, transferred and immunostained with polyclonal anti-Sco2.IgG. The position of msimilar kinetic pattern of intracellular delivery of fusion L-Sco2
protein to that seen in U-87 MG cells (Fig. 6). Moreover, in the case
of T24 cells, the presence of the fusion L-Sco2 protein was veriﬁed by
western blot immunostaining analysis using both polyclonal anti-
Sco2.IgG (Fig. 6A) and mouse monoclonal anti-HA.IgG (Fig. 6B).
3.4. Transduction of fusion L-Sco2 protein in transiently SCO2 mRNA
depleted and thus COX deﬁcient human K-562 cells
Since mitochondrial Sco2 protein plays a critical role in the as-
sembly of COX holoenzyme, it was interesting to investigate whether
the transduced recombinant fusion L-Sco2 protein can be functional
and able to contribute to COX enzymatic activity. Therefore, it was
critical to design an experimental approach to transiently suppress the
steady state levels of SCO2 mRNA transcripts and thus deplete targeting analysis of endogenous mature Sco2 protein in cytoplasmic protein extracts, derived
62, U-87 MG, T24 and 293T cell lines were electrophoretically separated on 1.2% w/v
C with [a-32P]dCTP labelled DNA fragment (836 bp) of SCO2 gene. The membranes were
romide staining patterns of electrophoresed RNA samples (the positions of 28S and 18S
-87 MG, T24, Hep G2 and 293T cell lines were electrophoretically separated on 12% w/v
ature Sco2 protein is shown by the arrow on the right.
Fig. 5.Western blot immunostaining detection of fusion L-Sco2 protein in the mitochondrial and cytosolic fractions derived from U-87 MG cells, using the polyclonal anti-Sco2.IgG.
Cultured U-87 MG cells were incubated with 10 µg/ml of solubilised fusion L-Sco2 protein for different time points. By the end of the incubation period, mitochondrial and cytosolic
proteins were isolated and fusion L-Sco2 protein was detected by western blot immunostaining analysis. M: Molecular Protein Weight Markers (lane 1); control: proteins
from untreated U-87 MG cells (lane 2); proteins from U-87 MG cells incubated with fusion L-Sco2 protein for 15 and 30 min, 1, 2 and 18 h (lanes 3, 4, 5, 7, 8, respectively); proteins
from U-87 MG cells incubated for 1 and 18 h with 20 mM of 1 M L-Arg (lanes 6, 9). (A) Mitochondrial proteins (∼10 µg) immunostained with polyclonal anti-Sco2.IgG. (B) Cytosolic
proteins (∼200 µg) immunostained with polyclonal anti-Sco2.IgG. (C) Cytosolic proteins (∼200 µg) immunostained with monoclonal anti-tubulin.IgG.
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least for several hours. To this end, we further exploited our recent
observation on Imatinib (IM) [37] showing that this agent besides
being a highly selective Bcr-Abl tyrosine kinase inhibitor used as an
effective agent in chronic myelogenous leukemia (CML), also lowers
selectively the steady state levels of SCO2 mRNA transcripts among
several others in IM-treated K-562 cells. K-562 cells treated with IM
(1 µM) for 48 and 72 h, regrown in IM-free conditions for 12, 24 and
48 h, as illustrated in Fig. 7A, and then assessed by RT-PCR for SCO2 gene
expression as well as mRNA transcripts encoded by: a) three other COX
assembly genes (SCO1, COX10, and COX17), b) three COXmitochondrialFig. 6. Western blot immunostaining detection of fusion L-Sco2 protein in the
mitochondrial and cytosolic fractions derived from T24 cells using the polyclonal
anti-Sco2.IgG and the monoclonal anti-HA.IgG. Cultured T24 cells were incubated with
10 µg/ml of solubilised fusion L-Sco2 protein for different time points. By the end of the
incubation period, mitochondrial and cytosolic proteins were isolated and fusion L-Sco2
protein was detected by western blot immunostaining analysis. M: Molecular Protein
Weight Markers (lane 1); control: proteins from untreated T24 cells (lane 2); Proteins
from T24 cells incubated with fusion L-Sco2 protein for 30 min, 1, 2 and 18 h (lanes 3, 4,
6, 7, respectively); proteins from T24 cells incubated for 1 and 18 h with 20 mM of 1 M
L-Arg (lanes 5, 8). (A) Mitochondrial proteins (∼18 µg) immunostained with polyclonal
anti-Sco2.IgG. (B) Mitochondrial proteins (∼18 µg) immunostained with monoclonal
anti-HA.IgG. (C) Cytosolic proteins (∼200 µg) immunostained with polyclonal anti-
Sco2.IgG. (D) Cytosolic proteins (∼200 µg) immunostained with monoclonal anti-
tubulin.IgG.genes (MTCOXI, MTCOXII, and MTCOXIII) and c) four COX nuclear-
structural genes (COXIV-1, COXVa, COXVIa-1, and COXVIc). As shown in
Fig. 7B, IM caused selective depletion of SCO2 mRNA levels, without
affecting the pattern of expression of eleven other genes. These cells
were also found to be COX deﬁcient (Fig. 8D).
Under these conditions, K-562 cells transiently depleted of SCO2
mRNA transcripts were suitable for transduction with fusion L-Sco2
protein, processed with Factor Xa protease (as described in Section 2).
Immediately after IM removal (Fig. 8A), at time zero (0 h), fusion L-Sco2
protein (20 µg/ml culture) was added for 4, 12 and 24 h. K-562 cells,
incubated either with mock bacteria-derived IBs (solubilised in 1 M
L-Arg) for 4 and 24 h or with 50 mM of 1 M L-Arg solution alone for
12 h, served as control experiments. All these cells were tested for
changes in cell growth and viability, endogenous Sco2 protein levels
as well as COX enzymatic activity. Transduction of fusion L-Sco2
protein in transiently SCO2mRNA depleted K-562 cells did not cause
any detectable effects in cell growth (data not shown) and viability
beyond those induced by IM pre-treatment (Fig. 8B). Western blot
immunostaining analysis with polyclonal anti-Sco2.IgG conﬁrmed
the absence of endogenous Sco2 protein in IM-treated cells for 72 h
(Fig. 8C, lane 4), indicating that such cells were Sco2 protein depleted,
prior to transduction with fusion L-Sco2 protein. However, when the
fusion L-Sco2 protein was transduced in K-562 cells, transiently SCO2
mRNAdepleted by IMand regrown in IM-freemedium, an intense band
corresponding tomatureproteinwas clearlydetected after 24 h (Fig. 8C,
lane 8). Whether this band, shown by the arrow, represents only
endogenous mature Sco2 protein (Mw ∼25 kDa) or a mixture of
endogenous mature Sco2 as well as Sco2-HA protein (Mw ∼27 kDa),
released after processing by MPP inside mitochondria of exogenously
added fusion L-Sco2 protein, is not clear. More important, in terms of
COX activity levels, cells grown in IM-free conditions and subsequently
transduced with the processed fusion L-Sco2 protein for 4, 12 and 24 h
exhibited substantial recovery (30–50%) of already suppressed COX
activity in cells pre-exposed to IM treatment (Fig. 8D). These data
indicate that the transduced fusion L-Sco2 protein contributed to the
recovery of COX activity, even within 4 h following transduction. The
magnitude of COX deﬁciency (∼70–80%) in K-562 cells, however,
induced by IM treatment remained almost unchanged after incubation
of these cellswith eithermockbacteria derived IBs (4and24 h)or 1 ML-
Arg solution alone (12 h) under IM-free conditions. These ﬁndings
indicate that the transduced fusion L-Sco2 protein contributed to partial
recovery of COX enzymatic activity in K-562 cells, although real
Fig. 7. RT-PCR assessment of mRNA levels of SCO2, SCO1, COX10, COX17, MTCOXII, MTCOXIII, MTCOXIII, COXIV-1, COXVa, COXVIa-1, COXVIc and GAPDH in human K-562 cells treated
transiently with Imatinib (IM). Human K-562 cells, treated ﬁrst with IM (1 µM) for 72 h and then grown in IM-free conditions for 12, 24 and 48 h (panel A), were assessed for the
intracellular levels of endogenous SCO2mRNA by RT-PCR analysis (panel B). Determination of mRNA levels for SCO1, COX10, COX17,MTCOXII,MTCOXIII, MTCOXIII, COXIV-1, COXVa,
COXVIa-1, COXVIc and GAPDH were also assessed (panel B).
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was still missing, presumably due to the lack of a discrete detectable
band at 27 kDa (Fig. 8C). To further examine whether K-562 cells
transduced with fusion L-Sco2 protein affect the steady state levels of
endogenous SCO2 mRNA transcripts, additional RT-PCR analysis was
also performed. The data obtained indicated that cells transduced with
L-Sco2 protein exhibited higher levels of endogenous SCO2 mRNA
transcripts, as compared to cells treated eitherwithmock-derived IBs or
L-Arg solution alone (Fig. 8E).
3.5. Successful processing of imported fusion L-Sco2 protein inside
mitochondria
To examine the possibility of the transduced fusion L-Sco2 protein
being imported inside the mitochondria and processed by MPP ap-
propriately in order to yield the corresponding mature Sco2-HA
protein, [35S]Methionine-labelled fusion L-Sco2 protein was produced
in a cell free system via in vitro transcription/translation of TAT-L-SCO2-
HA sequence in pET16b expression vector. In parallel, [35S]Methionine-
labelled L-Sco2 protein was produced via in vitro transcription/
translation of L-SCO2 sequence in pcDNA3 expression vector. As
shown in Fig. 9 (lanes 1, 3), both L-Sco2 as well as fusion L-Sco2
(His10-XaSITE-TAT-L-Sco2-HA) proteins, were labelled with [35S]Methi-
onine for 90 min at 30 °C and expressed successfully in vitro (30 and
36 kDa, respectively). Following incubation of [35S]Methionine-labelled
L-Sco2 and fusion L-Sco2 proteins for 2 h at 30 °C with isolated intact
mitochondria, derived fromK-562 cells and treatmentwith PK to digestany excess of protein not imported inside mitochondria. SDS-PAGE
analysis indicated that the imported proteins were successfully
processed to give the corresponding mature counterparts, Sco2
(25 kDa) and Sco2-HA (27 kDa) (Fig. 9, lanes 2, 4).
3.6. Intracellular delivery of fusion L-Sco2 protein and recovery of COX
activity in primary ﬁbroblasts derived from SCO2 deﬁcient patient
Histochemical analysis of COX enzymatic activity of primary ﬁ-
broblasts, derived from SCO2/COX deﬁcient patient (with 30%
residual COX activity in ﬁbroblasts compared to control ﬁbroblasts
[1]), grown on glass coverslips and incubated for 18 h with fusion L-
Sco2 protein (10 µg/ml culture), showed an increased staining for
COX (Fig. 10, panel C), suggesting intracellular delivery of fusion L-
Sco2 protein and recovery of COX activity.
Furthermore, these primary ﬁbroblasts were incubated with
10 µg/ml culture of fusion L-Sco2 protein (processed with Factor Xa
protease) for 4, 12 and 24 h. Cells incubated either with mock
bacteria-derived IBs (solubilised in 1 M L-Arg) for 4 and 24 h or with
30 mM L-Arg for 12 h, served as control experiments. All these cells,
regardless of treatment, were tested for changes in cell growth and
viability, intracellular delivery of fusion L-Sco2 protein as well as COX
enzymatic activity. Transduction of fusion L-Sco2 protein in these
primary ﬁbroblasts did not cause any detectable effects on cell growth
and viability (data not shown).Western blot immunostaining analysis
with the use of polyclonal anti-Sco2.IgG conﬁrmed the presence of
recombinant fusion L-Sco2 protein (Mw ∼36 kDa) in the mitochondria
Fig. 8. Effect of the transduced fusion L-Sco2 protein on the recovery of COX activity in transiently SCO2 depleted and thus COX suppressed human K-562 cells. Human K-562 cells
growing in culture were ﬁrst exposed to IM (1 µM) for 72 h. IMwas then removed, cells were washed, regrown in IM-free medium and incubated either a) with 20 µg/ml of fusion L-
Sco2 protein (processed with Factor Xa protease) or b) with mock bacteria-derived IBs (solubilised in 1 M L-Arg) for 4 and 24 h or c) with 50 mM of 1 M L-Arg solution alone for 12 h
(panel A). By the end of the incubation period, cells were assessed for viability (panel B), mitochondria were isolated and mature Sco2 protein was detected by western blot
immunostaining analysis using the polyclonal anti-Sco2.IgG (panel C). Such cells were also assessed for COX activity, expressed as a change of COX activity normalized to citrate
synthase activity (COX/CS) (each point represents the mean value of two different experiments) (panel D). Finally, cells were assessed for the intracellular steady state levels of
endogenous SCO2 and GAPDH transcripts by RT-PCR analysis (panel E). (panel C): lane 1: ∼2 µg of mature Sco2 protein [3]; lane 2: Molecular Protein Weight Markers; lane 3:
mitochondrial proteins (∼15 µg) from untreated K-562 cells (control); lane 4: mitochondrial proteins (∼15 µg) from K-562 cells incubated with IM (1µΜ) for 72 h; lane 5:
mitochondrial proteins (∼15 µg) from K-562 cells regrown in IM-free medium, incubated with 50mM L-Arg for 12 h; lane 7: mitochondrial proteins (∼15 µg) from K-562 cells
regrown in IM-free medium, incubated withmock-derived IBs for 24 h; lanes 6, 8: mitochondrial proteins (∼15 µg) from K-562 cells regrown in IM-free medium and incubated with
20 µg/ml of fusion L-Sco2 protein for 12 and 24 h, respectively. ⁎ f L-Sco2: fusion L-Sco2 protein.
Fig. 9. Processing of L-Sco2 and fusion L-Sco2 proteins inside isolated mitochondria,
derived from human K-562 cells. In vitro translation of L-SCO2 sequence in pcDNA3 (as
positive control) and TAT-L-SCO2-HA sequence in pET-16b was performed using
the TNT®T7 Quick Coupled Transcription/Translation System in the presence of [35S]
Methionine for 90 min at 30 °C. Corresponding translation products [lane 1: L-Sco2
(30 kDa), lane 3: fusion L-Sco2 (36 kDa)] were incubated with isolated intact
mitochondria, derived from Κ-562 cells and resuspended (∼10 µg/µl) in Mitochondrial
Import Buffer, for 2 h at 30 °C. After incubation with PK for 15 min on ice and
centrifugation at 10 000 ×g for 10 min at 4 °C, mitochondria were repelleted, analysed
with SDS-PAGE analysis and autoradiographed [lane 2: Sco2 (25 kDa), lane 4: Sco2-HA
(27 kDa)].
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protein for 12 and 24 h (Fig. 11A, lanes 6, 7).
More importantly, these primary cells, transduced with the
processed fusion L-Sco2 protein for 4, 12 and 24 h, exhibited increased
COX enzymatic activity, as shown biochemically against reduced
cytochrome c (Fig. 11B). In more details, a normalized COX/CS value
of 0.4 in three separate experiments (n=3) for patient primary
ﬁbroblast cells was increased to 1.85 (n=2), 2.8 (n=2) and 0.9
(n=2) after incubation with fusion L-Sco2 protein for 4, 12 and 24 h,
respectively.4. Discussion
Mitochondria are the power fuels of the cells, playing also a vital role
in central cellular pathways, like the Krebs cycle and programmed cell
death (apoptosis). Defects in genes (either of mitochondrial or nuclear
origin) encoding the numerous mitochondrial proteins, result in a wide
range of degenerative human disorders [38]. Although there is no cure
for themitochondrial diseases as yet, a number of approaches applied to
Fig. 10.Histochemical assessment of COX activity in SCO2 deﬁcient primary ﬁbroblasts after transduction with fusion L-Sco2 protein. Primary ﬁbroblasts, derived from SCO2 deﬁcient
patient M.C. [1], grown in coverslips and incubated for 18 h with 10 µg/ml fusion L-Sco2 protein were histochemically stained more intense for COX activity (panel C). Primary
ﬁbroblasts exposed to none (panel A) or incubated with ∼30mM L-Arg for 18 h (panel B) served as control experiments (40× magniﬁcation).
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[8,39]. The development of a model system for delivering recombinant
mitochondrial proteins inside the mitochondria of cells, in order to
replace the aberrant or deﬁcientmitochondrial proteins by their normalFig. 11. Detection of transduced recombinant fusion L-Sco2 protein into mitochondria
of primary ﬁbroblasts derived from SCO2 deﬁcient patient. Primary ﬁbroblasts grown in
culture were incubated either a) with 10 µg/ml fusion L-Sco2 protein (processed with
Factor Xa protease) or b) with mock bacteria-derived IBs (solubilised in 1 M L-Arg) for 4
and 24 h or c) with 50mM L-Arg for 12 h. By the end of the incubation period, cells were
assessed for viability (data not shown), mitochondria were isolated and the levels of
transduced fusion L-Sco2 protein were detected by western blot immunostaining
analysis using the polyclonal anti-Sco2.IgG (panel A). Lane 1: ∼0.1 µg of mature Sco2
protein [3]; lane 2: Molecular Protein Weight Markers; lane 3: mitochondrial proteins
(∼5.5 µg) from untreated primary patient cells; lane 4: mitochondrial proteins
(∼5.5 µg) from primary patient cells, incubated with 30mM L-Arg for 12 h; lane 5:
mitochondrial proteins (∼5.5 µg) from primary patient cells incubated with mock-
derived IBs for 24 h; lanes 6, 7: Mitochondrial proteins (∼5.5 µg) from primary patient
cells incubated with 10 µg/ml of fusion L-Sco2 protein for 12 and 24 h, respectively;
lane 8: ∼0.3 µg of fusion L-Sco2 protein (IBs enriched in fusion L-Sco2 protein and
solubilised in 1 M L-Arg). Such transduced cells were also assessed for COX activity,
expressed as a change of COX activity normalized to citrate synthase activity (COX/CS)
[points for patient ﬁbroblasts, mock (4 h) and L-Arg (12 h) represent the mean value of
three different experiments, while points for mock (24 h) and fusion L-Sco2 protein (4,
12, 24 h) represent the mean value of two different experiments] (panel B). ⁎ f L-Sco2:
fusion L-Sco2 protein.counterparts and then minimize the mitochondrial dysfunction or
restore normal mitochondrial function, is of major importance [40,41].
As an approach to encounter mitochondrial disorders due to
pathogenic mutations detected in SCO2 gene [1,2], we applied the PTD
technology to transduce recombinant mitochondrial full length L-
Sco2 protein fusedwith HIV-1 TAT-derived PTD into themitochondria
of eukaryotic cells. We were aware prior to the beginning of this
project that native Sco2 mitochondrial protein is a transmembrane,
relatively hydrophobic and hard to dissolve, protein [3]. Notably,
other investigators working with Sco2 have produced in bacteria only
the soluble fraction (79–266aa) [4] of this protein. Therefore, it was
quite a challenge to go on to produce in bacteria the full length L-Sco2
protein even in a fusion form. Using the pTAT/pTAT-HA vector and the
bacterial expression vector pET-16b, we were able to clone and
produce recombinant His10-XaSITE-TAT-L-Sco2-HA (fusion L-Sco2)
protein. Possible post-translational modiﬁcations of the Sco2 protein
in mammalian cells have not been taken in account in the present
study. According to Hu et al. [42], glycosylation of mitochondrial
proteins is not well studied till yet. Sco2 is a nuclear DNA encoded
mitochondrial protein and according to protein bioinformatic tools
(http://www.cbs.dtu.dk/researchgroups/protfunction.php), there
are no predicted glycosylation sites. This is correlated with SDS-
PAGE analysis of human recombinant wild-type Sco2 mature protein
[3], which runs at the same position with endogenous Sco2 protein
(Fig. 8C, lane 1). Since the recombinant fusion L-Sco2 protein (Fig. 1D)
was produced mainly in bacterial IBs (Fig. 2), highly puriﬁed IBs,
enriched in fusion L-Sco2 protein, were solubilised successfully in 1 M
L-Arg (Fig. 4, lane 1) and remained stable for at least 2 months at RT,
thus resolving the difﬁcult task of recombinant protein's solubility.
Although the solubilisation of recombinant fusion L-Sco2 protein in L-
Arg solution might be explained by an interaction between the
guanidium group of arginine and the side chain of the aromatic amino
acid tryptophan [43] [fusion L-Sco2 protein contains four tryptophans,
two of them located within the leader (L) peptide], the real
mechanism is not yet clear. We must mention also that L-Arg solution
has been already used in clinical practice, i.v. or per os, e.g. for the
treatment of stroke-like episodes in MELAS, a mitochondrial disorder
[44] and for haemolytic diseases [45].
The transduction of fusion L-Sco2 protein into U-87 MG and T24
adherent human cell lines was found to be time- and/or concentra-
tion-dependent. Transduction experiments were also performed with
human K-562 erythroleukemia cells. By using this cell system and
exploiting the unique ability of antileukemic agent IM to suppress
selectively SCO2 gene expression, as shown in Fig. 7 [without affecting
the expression of other ten COX genes (nuclear as well as mito-
chondrial) studied in parallel], we were able to demonstrate that the
transduction of exogenously added recombinant fusion L-Sco2
protein facilitated partial recovery of COX activity in such cells. Of
course, we are all aware that IM as an inhibitor can also cause other
507P.F. Foltopoulou et al. / Biochimica et Biophysica Acta 1802 (2010) 497–508cellular events. However, under these conditions it is reasonable to
assume that partial recovery of temporally suppressed COX activity by
IM can be attributed to the processed mature Sco2-HA protein inside
mitochondria (Fig. 8). The latter was supported by the ﬁnding of the in
vitro produced [35S]Methionine-labelled fusion L-Sco2 protein, which
was efﬁciently processed to the corresponding mature form, after
incubation with isolated intact mitochondria derived from human K-
562 cells (Fig. 9). This study suggests that the recombinant fusion L-
Sco2 proteinwas processed insidemitochondria like the native L-Sco2
protein, thus contributing to COX assembly and reactivity. Interest-
ingly, successful transduction of fusion L-Sco2 protein (Fig. 11A, lanes
6, 7) and recovery of COX activity was also achieved (Figs. 10 and 11B)
in primary ﬁbroblasts derived from SCO2 deﬁcient patient with
compound heterozygous (Q53X and E140K) mutations [1] suffering
from COX deﬁciency. The COX activity increased 4 to 12 h following
fusion L-Sco2 protein transduction. However, 24 h following fusion L-
Sco2 protein transduction, COX activity levels seem to be reduced.
Whether this reduction is attributed to the turnover of transduced
fusion L-Sco2 protein within the mitochondrial microenvironment or
to other factors, remain to be seen.
In contrast to the protein replacement therapy (applied success-
fully for missing proteins like peptide hormones, cytokines and
growth factors that act at the cell surface via receptors), therapy of
metabolic/genetic disorders, attributed to the lack of intracellular
proteins (acting like transcription factors, metabolic activators or
enzyme proteins) is still missing. Recombinant forms of such proteins
can be transduced via PTD technology intracellularly, processed
appropriately, remain stable and deliver their indented function.
Under such circumstances, protein delivery can be a fruitful approach
to treat disorders (like fatal infantile cardioencephalomyopathy [1])
caused by either malfunctioned intracellular proteins or deletion of
such proteins in other cases [12,15].
Thus, this study provides a model system for future protein ther-
apy of mitochondrial respiratory chain disorders via transduction of
recombinant mitochondrial proteins.
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